Royal DSM, the Life Sciences and Materials Sciences company, today reported a second quarter EBITDA of EUR345 million compared to EUR290 million in Q2 2012 and EUR311 million in Q1 2013. The improvement compared to Q2 2012 was realized despite a negative caprolactam effect of EUR20 million and a challenging macro-economic environment, which mainly affected Materials Sciences.
URL:
www.marketwire.com/press-release/dsm-delivers-higher-profits-full-year-outlook-unchanged-amsterdam-dsm-1817778.htm
No comments:
Post a Comment